Download GBM

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
An Overview of Glioblastoma (GBM)
Marci Klaassen, MSN and Allen Waziri, MD
Department of Neurosurgery
University of Colorado School of Medicine
Background
Glioblastoma : the miserable truth
• The most common primary brain tumor (~300 new cases in Colorado per
year)
• Incidence is highest in patients 45-55 years old – “prime of life”
• Median survival 15 months with best current therapy
• Hallmarks of tumor:
– Aggressive, infiltrative growth with necrosis of tumor (hypoxia)
– Significant vasogenic edema
– Copious microvascular proliferation
Increased metabolic demand
Necrosis
Microvascular proliferation
Basic pathology and physiology
• GBM starts from cells of the brain (stem cells?)
• Demonstrates infiltrative growth – “like mixing black and white sand
together” – makes differentiation from normal brain extremely difficult
• Most of the time occurs spontaneously (“primary”), but can also arise
from more low grade gliomas (“secondary)
• Virtually ALL low-grade tumors will progress to GBM, and clinical course
at that point is identical
• Few known risk factors
– Rare genetic traits (Li-Fraumini syndrome, etc.)
– Exposure to ionizing radiation (i.e. childhood treatment, etc.)
– No good data for association with cell phone use
Clinical Presentation
Rapidly progressive neurological symptoms depending
on the location of the tumor:
•
•
•
Seizure
Headache
Frontal lobe:
–
–
–
•
Parietal lobe:
–
–
–
–
•
Emotional lability
Memory loss
Visual impairment
Occipital lobe:
–
•
Altered sensation
Language/reading disturbances
Problems with spatial orientation
Difficulty with calculations
Temporal lobe:
–
–
–
•
Paralysis
Language/writing disturbances
Personality /cognitive changes
Visual impairment
Brainstem:
–
–
–
Double vision
Problems swallowing
Changes in speech
Brain Tumor Symptoms
• Irritation
– Seizures
• Pressure
– Edema
– Direct mass effect
• Destruction
Standard Treatment
Treatment of glioblastoma
Prognosis -> poor.
Treatment:
Surgery (debulking/cytoreductive)
Radiation (fractionated/IMRT)
Chemotherapy (Temodar, Avastin)
Tumor recurrence
Experimental therapy
DEATH (mean 15.4 months)
New treatment options are desperately needed
Clinical Course
Recovery from Surgery
•
•
•
•
•
•
Post-operative pain
Anti-epileptic medications
High potency steroids
Treatment planning
Wound healing
Ramifications of diagnosis:
– Emotional
– Social
– Financial
Side Effects
Chemotherapy:
Radiation Therapy:
•
•
•
•
•
•
•
Short-term:
•Hair loss
•Skin irritation
•Nausea
•Fatigue
Long-term:
•Neurological compromise
•Radiation necrosis
Nausea/vomiting
Constipation
Headache
Rash
Fatigue
Joint pain
Myelosuppression
– Anemia
– Infection
– Bleeding
Disease Progression
•
•
•
•
•
Tumor recurrence
Additional treatment
Progression of neurological symptoms
Decreased ability to function independently
Death
Experimental Therapy
Experimental options for GBM
• “Biological” agents
– Designed to target specific receptors/growth
factors/pathways
– May be antibody, small molecule, etc. mediated
• Loco-regional therapy
– Gliadel wafers, brachytherapy
•
•
•
•
Convection-enhanced delivery
Virotherapy
Nanoparticles
Immunotherapy – tumor vaccines, immunomodulation
Advantages of immunotherapy
Sensitivity, specificity and “memory”
“Natural” – the response of evolution to cancer
Requirements for an effective immune response
(and therefore effective immunotherapy):
Source of antigen
Clearly present in GBM – EGFRvIII, etc.
Immuno-Accessible environment
Is the brain a site of immunoprivilege? Not really.
Functional Immune System
Nov 2011
SUPPRESSION OF ENDOGENOUS
CELLULAR IMMUNITY
GBM
Neutrophil
activation
SUPPRESSION OF
VACCINES/IMMUNOTHERAPY
A Randomized Placebo-Controlled Trial Exploring the Efficacy of
Oral Arginine Supplementation to Improve Cellular Immune
Function in Patients with Glioblastoma Multiforme
Thank you – questions?